Drug Details

General Information of the Drug (ID: DR5762)
Name
Trimetazidine
Synonyms
TRIMETAZIDINE; 5011-34-7; 1-(2,3,4-Trimethoxybenzyl)piperazine; 1-[(2,3,4-trimethoxyphenyl)methyl]piperazine; 1-(2,3,4-Trimethoxy-benzyl)-piperazine; UNII-N9A0A0R9S8; Piperazine, 1-((2,3,4-trimethoxyphenyl)methyl)-; N9A0A0R9S8; Vasartel; Piperazine, 1-[(2,3,4-trimethoxyphenyl)methyl]-; Trimetazidina; Trimetazidinum; MLS001240268; Trimetazidinum [INN-Latin]; Trimetazidina [INN-Spanish]; Trimetazidine [INN:BAN:DCF]; 1,2,3-trimethoxy-4-(piperazinylmethyl)benzene; NCGC00016697-01; SMR000674573; EINECS 225-690-2; CAS-13171-25-0; Preductal; Vasorel; Preductal MB; Dilatan (TN); Trimetazidine (INN); BAS 06612844; Prestwick0_000549; Prestwick1_000549; Prestwick2_000549; Prestwick3_000549; Oprea1_279550; Piperazine,1-[(2,3,4-trimethoxyphenyl)methyl]-; BSPBio_000597; MLS001331735; SCHEMBL230374; SPBio_002518; BPBio1_000657; CHEMBL203266; DTXSID2048531; BDBM80613; CHEBI:94789; cid_9926449; HY-B0968A; HMS2230L07; HMS3374D04; ALBB-004703; BCP16534; BBL013084; MFCD00868263; s5779; SBB007020; STK315643; ZINC19358638; AKOS000308094; 4-(2,3,4-Trimethoxybenzyl)piperazine; DB09069; MCULE-9820869946; 1-(2,3,4-trimethoxy benzyl)piperazine; NCGC00016697-02; SMR000814701; 1-(2,3,4-trimethoxyphenyl)methylpiperazine; 1-(2,3,4-trimethoxyphenylmethyl)piperazine; AB0111344; DB-051731; BB 0220635; CS-0099250; R3927; ST45134749; EN300-14439; 71T250; A25088; D08642; A827982; A837947; Q674703; 1-(2,3,4-trimethoxybenzyl)piperazine;hydrochloride; 1-[2,3,4-trimethoxybenzyl] piperazine dihydrochloride; BRD-K88366685-300-03-7; BRD-K88366685-300-04-5; Z99601262; 1-[(2,3,4-trimethoxyphenyl)methyl]piperazine;hydrochloride; 1-((2,3,4-trimethoxyphenyl)methyl)-piperazindihydrochloride;1-(2,3,4-trimethoxybenzyl)-piperazindihydrochloride; 127881-54-3
    Click to Show/Hide
Molecular Type
Small molecule
Disease Angina pectoris [ICD-11: BA40] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C14H22N2O3
PubChem CID
21109
Canonical SMILES
COC1=C(C(=C(C=C1)CN2CCNCC2)OC)OC
InChI
1S/C14H22N2O3/c1-17-12-5-4-11(13(18-2)14(12)19-3)10-16-8-6-15-7-9-16/h4-5,15H,6-10H2,1-3H3
InChIKey
UHWVSEOVJBQKBE-UHFFFAOYSA-N
CAS Number
CAS 5011-34-7
ChEBI ID
CHEBI:94789
TTD Drug ID
D0Q4YI
DrugBank ID
DB09069
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Naringin      Citrus x rokugatsu     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Forty male Sprague-Dawley rats weighting ranged from 200 to 250 g were used in this study.
                    Experimental
                    Result(s)		 NAR, TMZ, or their combination could attenuate the Nrf-2 expression in the kidney tissue, following the renal IR injury through inhibition of lipid peroxidase, and enhancement of antioxidant activity.
          Alprostadil + Plasmin     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Experimental
                    Result(s)		 Trimetazidine and plasmin combined with alprostadil can effectively treat lower extremity arteriosclerosis obliterans.
          Malic acids + Succinic acids     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [4]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model The study was carried out on 40 male Wistar rats (230-250 g).
                    Experimental
                    Result(s)		 A mixture of mitochondrial substrates of succinic and malic acids more effectively than antihypoxant trimetazidine prevented functional and metabolic disorders in rat myocardium during acute ischemia.
References
Reference 1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Reference 2 Protective effects of naringin and trimetazidine on remote effect of acute renal injury on oxidative stress and myocardial injury through Nrf-2 regulation. Pharmacol Rep. 2019 Dec;71(6):1059-1066.
Reference 3 Efficacy of trimetazidine and plasmin combined with alprostadil in treatment of lower extremity arteriosclerosis obliterans. Exp Ther Med. 2019 Jun;17(6):4554-4560.
Reference 4 Cardioprotective effects of trimetazidine and a combination of succinic and malic acids in acute myocardial ischemia. Bull Exp Biol Med. 2008 Aug;146(2):218-22.
 Download Picture         KEGG Link